β-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor

Molecular Endocrinology

Volumn 19, Issue 2, 2005, Pages 391-398

  Verras, Meletios ^a   Sun, Zijie ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSACTIVATION; WILD TYPE;

ANIMALS; BETA CATENIN; BETA-GALACTOSIDASE; BLOTTING, NORTHERN; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; CYTOSKELETAL PROTEINS; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH SUBSTANCES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; LUCIFERASES; MALE; MUTATION; PEPTIDES; PLASMIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

ANIMALIA;

EID: 13544253453     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0208     Document Type: Article

References (33)

1. Kyprianou N, Isaacs JT 1988 Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562
2. Jenster G 1999 The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26:407-421
3. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
4. Playford MP, Bicknell D, Bodmer WF, Macaulay VM 2000 Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin. Proc Natl Acad Sci USA 97:12103-12108
5. Truica Cl, Byers S, Gelmann EP 2000 β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713
6. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z 2002 Linking β-catenin to androgen signaling pathway. J Biol Chem 277:11336-11344
7. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME 2002 Liganded androgen receptor interaction with β-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem 277:20702-20710
8. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC 2002 The androgen receptor can promote β-catenin nuclear translocation independently of APC. J Biol Chem 277:17933-17943
9. Polakis P 2000 Wnt signaling and cancer. Genes Dev 14:1837-851
10. Ozawa M, Baribault H, Kemler R 1989 The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8:1711-1717
11. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R 1997 β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797-3804
12. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H 1996 XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 86:391-399
13. Chesire DR, Isaacs WB 2002 Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 21:8453-8469
14. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC 2003 Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22:5602-5613
15. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, Klocker H 1995 Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 13:285-289
16. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, Li W 1999 Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 19:3816-3828
17. Stambolic V, Woodgett JR 1994 Mitogen inactivation of glycogen synthase kinase-3β in intact cells via serine 9 phosphorylation. Biochem J 303(Pt 3):701-704
18. Sutherland C, Leighton IA, Cohen P 1993 Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296(Pt 1):15-19
19. Stambolic V, Ruel L, Woodgett JR 1996 Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664-1668
20. Masiello D, Chen SY, Xu Y, Verthoeven MC, Choi E, Hollenberg AN, Balk SP 2004 Recruitment of β-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 18:2388-2401
21. Sanchez ER, Faber LE, Henzel WJ, Pratt WB 1990 The 56-59-kilodalton protein identified in untransformed steroid receptor complexes is a unique protein that exists in cytosol in a complex with both the 70- and 90-kilodalton heat shock proteins. Biochemistry 29:5145-5152
22. Zhou ZX, Wong CI, Sar M, Wilson EM 1994 The androgen receptor: an overview. Recent Prog Horm Res 49:249-274
23. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818
24. Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW 1993 Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 53:2852-2857
25. Reiss K, D'Ambrosio C, Tu X, Tu C, Baserga R 1998 Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4:2647-2655
26. Polakis P 1999 The oncogenic activation of β-catenin. Curr Opin Genet Dev 9:15-21
27. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M 1997 Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57:3189-3193
28. Datta SR, Brunet A, Greenberg ME 1999 Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
29. Cantley LC, Neel BG 1999 New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245
30. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L 2001 IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20:4942-4950
31. Sharma M, Li X, Wang Y, Zarnegar M, Huang CY, Palvimo JJ, Lim B, Sun Z 2003 hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J 22:6101-6114
32. Sharma M, Chuang WW, Sun Z 2002 Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 277:30935-30941
33. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkman AO, Trapman J 1996 Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specfic antigen promoter. J Biol Chem 271:6379-6388